z-logo
open-access-imgOpen Access
Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review
Author(s) -
Maartje M van de Meeberg,
Johannes P D Schultheiss,
Bas Oldenburg,
Herma H. Fidder,
Alwin D. R. Huitema
Publication year - 2019
Publication title -
digestion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.882
H-Index - 75
eISSN - 1421-9867
pISSN - 0012-2823
DOI - 10.1159/000499331
Subject(s) - mesalazine , medicine , ulcerative colitis , gastroenterology , inflammatory bowel disease , therapeutic effect , feces , aminosalicylic acid , drug , disease , colitis , randomized controlled trial , urine , pharmacology , paleontology , biology
Oral 5-aminosalicylic acid (5-ASA, mesalazine) is the first choice therapeutic agent for treating mild-to-moderate ulcerative colitis (UC). Unfortunately a significant group of patients fail to respond. Therapeutic drug monitoring might help to maintain or induce remission by providing a tool for optimization of 5-ASA therapy. However, plasma and urine concentrations of 5-ASA reflect systemic uptake and are not useful to evaluate therapeutic effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here